**IMMUNOCORE**

**Milton Park, Oxfordshire**

**ABOUT IMMUNOCORE**

Immunocore was founded in 2008, originally out of Oxford University, and is based just south of Oxford; it now has a vibrant, diverse workforce of over 140 members.

Immunocore is a dynamic, clinical-stage biotechnology company developing a highly innovative class of biologic drugs based on the company’s proprietary T Cell Receptor (TCR) technology, drugs which have the potential to treat cancer, viral infections and autoimmune diseases.

Immunocore’s world-leading science and strong IP position have resulted in discovery collaborations with major pharmaceutical companies including Genentech, GlaxoSmithKline, MedImmune, the biologics division of AstraZeneca, as well as a co-discovery and co-development partnership with Lilly. Immunocore is well-funded and owned by a group of long-term private investors.

**HEAD OF DEVELOPMENT**

In line with our world-leader aspirations, we are looking for an experienced and inspirational Head of Development to support the transition of the Immunocore early stage clinical development and pre-clinical portfolio through to late stage Development and eventual launch. As leader of a dedicated, enthusiastic group of scientists, the Head of Development will oversee the formulation and analytical development activities of the pre-commercialisation drug portfolio, including technical transfer and out-sourcing of GMP manufacture of Immunocore products.

Applicants will be well-qualified (higher academic degree), with a minimum of ten years’ experience leading drug development activities for the oncology market, particularly in the late-stage, ideally within both the big pharma and the biotech environment. They will have a keen interest in current scientific thinking in oncology and immune-oncology and a demonstrable ability to lead the assessment of the commercial potential of new drug products. They will be gifted communicators, commercially astute and exceptionally skilled in juggling priorities.

We are looking for someone exceptional and will make sure that the salary offered is commensurate with the calibre of the successful candidate. Company benefits include membership of company pension scheme, private health and income protection insurance and assistance with relocation expenses.

*To be considered for this position, please apply to Mrs C. Canuto, 90 Park Drive, Milton Park, Oxfordshire, OX14 4RS (e-mail: hr@immunocore.com).*

We will be holding first interviews in April.

---

**University of Glasgow**

**College of Medical, Veterinary and Life Sciences**

**Research Institute of Molecular Cell & Systems Biology**

**Bioinformatician**

Ref: 010231
Salary: Grade 6 £27,057 - £30,434 per annum

The post-holder will contribute to a Biotechnology and Biological Sciences Research Council-funded project FlyAtlas2, working with the Principal Investigator, Professor Julian Dow.

Specifically, this post requires expert knowledge high-level bioinformatic, web authoring and programming skills for this project to generate tissue-specific RNA-seq data for the model organism Drosophila melanogaster. This will provide an update to the worldwide online expression resource, flyatlas.org (Nature Genetics 39: 715-720).

There is considerable opportunity to produce novel meta-analyses of the resulting data, and the successful candidate will be expected to drive research to provide high-profile publications from the work, in addition to providing data analysis, web authoring and semantic web underpinnings for the resource. Although the workplan is primarily informatic in nature, there is also scope for a suitable candidate to perform some wet work (for example transcript validation by PCR, and generation of transgenic Drosophila).

The post-holder will also be expected to contribute to the formulation and submission of research publications and research proposals as well as help manage and direct this complex and challenging project, as opportunities allow.

This post is full time and funded for 18 months in the first instance.

*To apply please visit: [http://www.glasgow.ac.uk/connect/jobs](http://www.glasgow.ac.uk/connect/jobs)*

---

**University of Manchester**

**Professor in Industrial Biotechnology**

Ref: EPS-06135

**Salary will be on the Professorial scale from £62,840 per annum (according to relevant experience)**

The University of Manchester enjoys a global reputation for its research and its innovative approach to learning. It is home to the internationally renowned Manchester Institute of Biotechnology and a leading Chemical Engineering School. Industrial biotechnology is at its heart – identified as one of the key priority areas for growth within the University, backed by an on-going £1 billion investment on facilities, staff and buildings. We seek to appoint a visionary leader with a focus on Bioprocess Engineering and a demonstrable track record of innovation and leadership. The appointee will provide leadership for Industrial Biotechnology across the University.

**Closing date: 31 May 2015**

The University actively fosters a culture of inclusion and diversity and seeks to achieve true equality of opportunity for all members of its community. In addition, the School’s Athena SWAN Silver Award recognises its commitment to promote women in science, engineering and technology.

*To apply please visit: [http://www.manchester.ac.uk/connect/jobs](http://www.manchester.ac.uk/connect/jobs)*

---

**University of Oxford**

**Immunocore**

Immunocore was founded in 2008, originally out of Oxford University, and is now based south of Oxford; it now has a vibrant, diverse workforce of over 140 members.

Immunocore is a dynamic, clinical-stage biotechnology company developing a highly innovative class of biologic drugs based on the company’s proprietary T Cell Receptor (TCR) technology, drugs which have the potential to treat cancer, viral infections and autoimmune diseases.

Immunocore’s world-leading science and strong IP position have resulted in discovery collaborations with major pharmaceutical companies including Genentech, GlaxoSmithKline, MedImmune, the biologics division of AstraZeneca, as well as a co-discovery and co-development partnership with Lilly. Immunocore is well-funded and owned by a group of long-term private investors.

---

**Immunocore was founded in 2008, originally out of Oxford University, and is now based south of Oxford; it now has a vibrant, diverse workforce of over 140 members.**

Immunocore is a dynamic, clinical-stage biotechnology company developing a highly innovative class of biologic drugs based on the company’s proprietary T Cell Receptor (TCR) technology, drugs which have the potential to treat cancer, viral infections and autoimmune diseases.

Immunocore’s world-leading science and strong IP position have resulted in discovery collaborations with major pharmaceutical companies including Genentech, GlaxoSmithKline, MedImmune, the biologics division of AstraZeneca, as well as a co-discovery and co-development partnership with Lilly. Immunocore is well-funded and owned by a group of long-term private investors.

---

**University of Oxford**

**Immunocore**

Immunocore was founded in 2008, originally out of Oxford University, and is now based south of Oxford; it now has a vibrant, diverse workforce of over 140 members.

Immunocore is a dynamic, clinical-stage biotechnology company developing a highly innovative class of biologic drugs based on the company’s proprietary T Cell Receptor (TCR) technology, drugs which have the potential to treat cancer, viral infections and autoimmune diseases.

Immunocore’s world-leading science and strong IP position have resulted in discovery collaborations with major pharmaceutical companies including Genentech, GlaxoSmithKline, MedImmune, the biologics division of AstraZeneca, as well as a co-discovery and co-development partnership with Lilly. Immunocore is well-funded and owned by a group of long-term private investors.